InventoRR MD Inc. Receives Innovative Technology Contract from Vizient
TORONTO--(BUSINESS WIRE)-- InventoRR MD Inc. announced its AbClo, an open abdomen management and closure system, has received an Innovative Technology contract from Vizient, Inc. the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on review of AbClo from hospital experts who serve on one of Vizient's client-led councils, and it signifies to Vizient clients its unique qualities that potentially bring improvement to the healthcare industry.
InventoRR MD Inc. Receives Innovative Technology Contract from Vizient for AbClo, an Open Abdomen Management and Closure System.
Share
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient's Innovative Technology Program. Vizient client-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations.
'We are excited that AbClo has been accepted to the Vizient Innovative Technology Program and look forward to working with Vizient to continue AbClo's adoption and growth across their provider-client network. The Vizient Innovative Technology contract is a meaningful piece of validation for the potential impact AbClo brings to patients, surgeons and hospitals across North America.'
Chris Bass, CEO of InventoRR MD Inc.
AbClo represents a paradigm shift in the management and closure of intentionally left open abdomens, being the only non-invasive and preventative closure system on the market. By shifting away from reactive, invasive surgical techniques and devices, AbClo empowers hospitals and physicians to further improve patient outcomes and operational efficiencies.
In line with the Quadruple Aim in Healthcare Improvements, AbClo reduces patient length of stay, average surgical procedure volume and overall complication rates; helping improve hospital efficiencies and lightening provider workload. As a benefit of these improvements, AbClo works to save thousands of dollars in spending on materials, ICU stay and re-admission billing.
'After a review of AbClo, Vizient's client council agreed this technology offers a unique benefit over other products available in the market today and recommended it for an Innovative Technology contract. We are pleased to award this new contract to InventoRR MD Inc.' said Kelly Flaharty, senior director of contract services for Vizient.
Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with client-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.
InventoRR MD Inc. is a medical device manufacturer specializing in innovative devices in the trauma and acute care surgery field. Our flagship product, AbClo, is improving outcomes and promoting efficiencies in open abdomen management and recovery. With a strong base in academia and practical surgical experience, InventoRR MD brings innovative products to market with a focus on improving patients and physician experiences in complex surgeries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in
REYKJAVIK, Iceland--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article 'Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial' reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, 'Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation' describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, 'A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier ' reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: 'It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. 'The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. 'We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases.' Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: 'These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation.' About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.
Business Wire
2 hours ago
- Business Wire
KBRA Releases Global ABS 2025: Day 1 Recap
LONDON--(BUSINESS WIRE)--The Global ABS 2025 conference, held in Barcelona on 10-12 June, opened to a record 5,000+ registered attendees, including over 2,000 issuers and investors, as well as a full programme. The conference celebrated its 29th anniversary as the largest annual European structured finance conference and is hosted by the Association for Financial Markets in Europe (AFME). This year marks the first time the event is being organised by FT Live, following its takeover of the previous organiser, Invisso. Judging by the strong attendance and KBRA's very active meeting calendar, the industry event reflects the growth momentum experienced by European securitisation markets. New transaction issuance started the year on a strong note and, despite a temporary pause, continued to build a robust and positive pipeline of transactions across all product types. Day 1 panels featured market updates on asset-backed securities (ABS), collateralised loan obligations (CLO), commercial mortgage-backed securities (CMBS), nonperforming loans (NPL), and more. Other discussions included broader topics such as regulation and synthetic risk transfer (SRT) securities, including several plenary sessions. KBRA speakers featured on a number of important panels covering solar panel loans, CLOs, and residential mortgage-backed securities (RMBS) markets. Click here to view a recap of some of the day's panel discussions. Recent Publications About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1009819
